Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLosing 50 lbs on Wegovy typically takes somewhere between 12 and 24 months, depending on your starting weight, the dose your prescriber reaches, and how your body responds. That range comes directly from the STEP 1 clinical trial, where participants lost an average of around 15% of body weight over 68 weeks — which for someone starting at around 230 lbs works out to roughly 35 lbs at the average, and closer to 50 lbs or more for those who responded well. It is a prescription-only medicine, so a prescriber assesses suitability before any treatment starts — but the short answer to how long is: most people who reach and stay at the 2.4 mg maintenance dose see meaningful progress by six months and reach their larger goals, if clinically achievable, around the 12–18 month mark.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Fifty pounds is a specific number, but the way clinical trials measure Wegovy's effect is in percentage of starting body weight, and that framing matters a lot when you are trying to estimate a timeline. At 2.4 mg, the STEP 1 trial recorded an average reduction of around 15% of starting body weight at 68 weeks. If you start at 230 lbs, 15% is roughly 34 lbs. To reach 50 lbs, you would need to be above the average (around the 21–22% mark) which is where the top quarter of trial participants landed.
That is not discouraging. It means 50 lbs is achievable within the licensed trial period for a substantial number of people; it just is not the average outcome. Your starting weight changes the arithmetic too. Begin at 290 lbs and 15% loss is already 43 lbs, putting you within reach of 50 by the time your prescriber has held you at maintenance dose for a few extra months. How weight loss on Wegovy unfolds week by week is covered in more depth for those who want the finer picture.
One thing worth knowing: the STEP 1 figure is an average across all doses and all participants, including those who never reached 2.4 mg. Those who did reach and sustain the maintenance dose saw higher losses. Dose matters, which is why your prescriber's titration decisions are not a formality.
The pattern most people experience on Wegovy is front-loaded but gradual. In the first four weeks you are on the 0.25 mg starting dose, this exists to let your digestive system adjust, not to drive weight loss. Do not read the scales too closely at this stage. From weeks five through roughly twenty-four, as the dose steps up toward 2.4 mg, appetite suppression builds and weight typically drops fastest. Many people lose 1–2 lbs per week in this phase, sometimes more in the early weeks.
From month six onward, the rate usually slows. That is normal physiology, not a sign that Wegovy has stopped working. The body adapts to a lower calorie intake, and metabolic rate adjusts. If you want to understand how long it takes to lose weight on Wegovy across the full treatment period, the picture becomes clearer once you know how the slower second phase fits in. If you are aiming for 50 lbs and you have lost 30 by month six, the remaining 20 may take another six to twelve months at the maintenance dose.
The MHRA's April 2026 approval of the 7.2 mg single-dose pen is relevant here. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, which shortens the arithmetic for many people targeting 50 lbs. If your prescriber determines the higher dose is appropriate, the timeline shifts accordingly. Specific pen availability is confirmed at consultation.
You can read more about when most people first notice weight loss starting if you are earlier in the process.
There is an honest acknowledgement worth making here: if you are setting a target of 50 lbs, you have probably been working toward this for a while. Perhaps you have tried other routes, or you have read conflicting timelines online and found them frustrating. That is a reasonable place to be. The biology of weight loss is genuinely variable, and no medicine or service can give you a personal guarantee. What the evidence does support is that the people who reach large targets on Wegovy tend to share a few things in common.
Dose adequacy is one. Reaching and staying at the 2.4 mg (or higher) maintenance dose gives your body the full pharmacological signal. Stopping early, or pausing because of side effects without discussing them with a prescriber, limits what is possible. The nausea that can accompany a dose increase usually settles within a couple of weeks; managing it through meal size rather than stopping is usually more productive.
Protein and activity matter alongside the medicine. Wegovy reduces appetite across the board, which can mean muscle loss alongside fat if protein intake falls too low. A prescriber or dietitian can advise on practical targets. Our frequently asked questions cover some of the most common queries about managing diet alongside treatment.
For a broader view of how Wegovy works and what treatment involves, the pillar page covers the mechanism, eligibility, and what to expect across the full licensed period. And if the cost side of things is on your mind, how Wegovy pricing compares across UK providers is a sensible next read.
It depends almost entirely on your starting weight and which dose your prescriber can safely reach with you. For someone starting at or above 240 lbs, 50 lbs represents around 20% of body weight, within reach of the higher-responding trial participants on 2.4 mg, and increasingly likely territory for people who tolerate 7.2 mg. For someone starting at 190 lbs, 50 lbs is a 26% reduction, genuinely possible, but more likely at the upper end of the timeline or at the higher dose. If you are weighing up how long you would need to take Wegovy to reach your target, that question is worth exploring before you set your expectations around a specific number of months.
One way to think about the goal: NICE's appraisal of Wegovy notes that if someone has not lost at least 5% of starting body weight after six months at the maintenance dose, continuing is reviewed. That threshold is set because the medicine works for most people who reach an adequate dose; it is not a ceiling. If you are on track at six months, the 50 lb question becomes a matter of time rather than possibility.
A prescriber can give you a much more specific estimate once they know your starting weight, your dose trajectory, and your overall health picture. If you have been wondering whether treatment is right for you, starting a free consultation is how that conversation begins, at nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber, not automated. That is the honest starting point for any real timeline.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.